DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP - News), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced consolidated results for the second quarter of 2007 and for the six-month period ended June 30, 2007. For the second quarter of 2007, Neoprobe reported a net loss of $1.1 million or $0.02 per share compared to a net loss of $861,000 or $0.01 per share for the second quarter in 2006. For the six months ended June 30, 2007, Neoprobe reported a net loss of $2.2 million or $0.04 per share compared to a net loss of $1.8 million or $0.03 per share for the same period in 2006. The net loss for the second quarter of 2007 included $357,000 in non-cash charges compared to total non-cash charges of $348,000 for the second quarter of 2006. The net loss for the six-month period ended June 30, 2007 included $740,000 in non-cash charges compared to total non-cash charges of $745,000 for the same period in 2006. Non-cash charges for both periods consisted primarily of the amortization of warrant and debt-issuance costs related to the financing that was completed in December 2004 in addition to depreciation and amortization of fixed and intangible assets.
